CL2013000380A1 - Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion. - Google Patents

Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.

Info

Publication number
CL2013000380A1
CL2013000380A1 CL2013000380A CL2013000380A CL2013000380A1 CL 2013000380 A1 CL2013000380 A1 CL 2013000380A1 CL 2013000380 A CL2013000380 A CL 2013000380A CL 2013000380 A CL2013000380 A CL 2013000380A CL 2013000380 A1 CL2013000380 A1 CL 2013000380A1
Authority
CL
Chile
Prior art keywords
thiadiazine
schizophrenia
alzheimer
depression
medicine
Prior art date
Application number
CL2013000380A
Other languages
English (en)
Spanish (es)
Inventor
Masakuni Kori
Toshihiro Imaeda
Shinji Nakamura
Masashi Toyofuku
Eiji Honda
Yasutomi Asano
Osamu Ujikawa
Michiyo Mochizuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2013000380A1 publication Critical patent/CL2013000380A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CL2013000380A 2010-08-10 2013-02-07 Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion. CL2013000380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010179577 2010-08-10

Publications (1)

Publication Number Publication Date
CL2013000380A1 true CL2013000380A1 (es) 2013-05-31

Family

ID=44534564

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000380A CL2013000380A1 (es) 2010-08-10 2013-02-07 Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.

Country Status (39)

Country Link
US (11) US9150591B2 (cg-RX-API-DMAC7.html)
EP (1) EP2603513B1 (cg-RX-API-DMAC7.html)
JP (2) JP5788496B2 (cg-RX-API-DMAC7.html)
KR (1) KR101852215B1 (cg-RX-API-DMAC7.html)
CN (2) CN103180326B (cg-RX-API-DMAC7.html)
AR (1) AR082618A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011290126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013002250B1 (cg-RX-API-DMAC7.html)
CA (1) CA2807460C (cg-RX-API-DMAC7.html)
CL (1) CL2013000380A1 (cg-RX-API-DMAC7.html)
CO (1) CO6680700A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130066A (cg-RX-API-DMAC7.html)
CY (1) CY1123507T1 (cg-RX-API-DMAC7.html)
DK (1) DK2603513T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000030A (cg-RX-API-DMAC7.html)
EA (1) EA022078B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012478A (cg-RX-API-DMAC7.html)
ES (1) ES2793723T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20156216B (cg-RX-API-DMAC7.html)
HR (1) HRP20200844T1 (cg-RX-API-DMAC7.html)
HU (1) HUE049460T2 (cg-RX-API-DMAC7.html)
IL (1) IL224452A (cg-RX-API-DMAC7.html)
LT (1) LT2603513T (cg-RX-API-DMAC7.html)
MA (1) MA34509B1 (cg-RX-API-DMAC7.html)
MX (1) MX349470B (cg-RX-API-DMAC7.html)
MY (1) MY165908A (cg-RX-API-DMAC7.html)
NZ (1) NZ607593A (cg-RX-API-DMAC7.html)
PE (1) PE20131116A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500247A1 (cg-RX-API-DMAC7.html)
PL (1) PL2603513T3 (cg-RX-API-DMAC7.html)
PT (1) PT2603513T (cg-RX-API-DMAC7.html)
RS (1) RS60311B1 (cg-RX-API-DMAC7.html)
SG (1) SG187656A1 (cg-RX-API-DMAC7.html)
SI (1) SI2603513T1 (cg-RX-API-DMAC7.html)
TW (1) TWI504604B (cg-RX-API-DMAC7.html)
UA (1) UA111594C2 (cg-RX-API-DMAC7.html)
UY (1) UY33551A (cg-RX-API-DMAC7.html)
WO (1) WO2012020848A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301120B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200844T1 (hr) * 2010-08-10 2020-08-21 Takeda Pharmaceutical Company Limited Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora ampa-receptora
WO2012137982A2 (en) 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2013118845A1 (ja) * 2012-02-08 2013-08-15 武田薬品工業株式会社 複素環化合物およびその用途
US20150011554A1 (en) * 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
EA028637B1 (ru) 2013-06-27 2017-12-29 Пфайзер Инк. Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
HUE049827T2 (hu) 2013-12-03 2020-10-28 Fmc Corp Pirrolidinonok mint herbicidek
KR102479858B1 (ko) 2014-07-02 2022-12-21 에프엠씨 코포레이션 피페리디논계 제초제
CN107001260B (zh) 2014-12-08 2020-11-10 Fmc公司 3-氧基-3-(芳氨基)丙酸酯、其制备方法、以及其在制备吡咯烷酮中的用途
US10405547B2 (en) 2015-04-10 2019-09-10 Fmc Corporation Substituted cyclic amides as herbicides
US10582709B2 (en) 2015-04-27 2020-03-10 Fmc Corporation Butyrolactones as herbicides
WO2016176457A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
UA120304C2 (uk) * 2015-04-29 2019-11-11 Янссен Фармацевтика Нв Азабензімідазоли та їх використання як модуляторів рецепторів ampa
WO2016182780A1 (en) 2015-05-12 2016-11-17 E I Du Pont De Nemours And Company Aryl substituted bicyclic compounds as herbicides
EP3303287B1 (en) 2015-05-29 2020-12-16 FMC Corporation Substituted cyclic amides as herbicides
CN107709310B (zh) 2015-06-02 2021-09-24 Fmc公司 取代的环酰胺及其作为除草剂的用途
BR112018001964B1 (pt) 2015-07-31 2022-05-10 Fmc Corporation Composto, composição herbicida, mistura herbicida e método para o controle docrescimento de vegetação indesejada
EP3331892B1 (en) * 2015-08-06 2019-07-03 F.Hoffmann-La Roche Ag Processes for the preparation of galnac acid derivatives
US20170181292A1 (en) * 2015-12-16 2017-06-22 Rohm And Haas Electronic Materials Llc Method for forming organic coating on nickel surface
CN105669731B (zh) * 2016-01-10 2017-06-30 沧州普瑞东方科技有限公司 一种4‑(4‑烷基环己氧基)苯硼酸的合成方法
CN110312712B (zh) 2016-12-21 2023-06-23 Fmc公司 硝酮除草剂
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物
JP7201609B2 (ja) 2017-03-21 2023-01-10 エフ エム シー コーポレーション ピロリジノン及びこれらを調製するためのプロセス
MX2019011090A (es) 2017-03-21 2019-11-18 Fmc Corp Mezcla herbicida, composición y método.
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
EP3693360B1 (en) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EP3693368B1 (en) * 2017-10-06 2023-12-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
PL4031552T3 (pl) 2019-09-16 2025-03-17 Takeda Pharmaceutical Company Limited Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów
JP2023526249A (ja) * 2020-05-15 2023-06-21 武田薬品工業株式会社 うつ病の処置
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
WO2025224508A1 (en) 2024-04-22 2025-10-30 Takeda Pharmaceutical Company Limited Pharmaceutical composition for treating depressive disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0437742Y2 (cg-RX-API-DMAC7.html) 1986-10-22 1992-09-04
JPH0285851A (ja) * 1988-09-22 1990-03-27 Konica Corp 新規な写真用カプラー
JPH037742A (ja) 1989-06-05 1991-01-14 Toyo Tire & Rubber Co Ltd ラバーチエーン用ゴム組成物
JP2874960B2 (ja) * 1990-06-03 1999-03-24 コニカ株式会社 新規な染料を含有するハロゲン化銀写真感光材料
JPH04119890A (ja) * 1990-09-11 1992-04-21 Konica Corp ピラゾロチアジアジン系色素
JP3430375B2 (ja) * 1993-11-12 2003-07-28 コニカ株式会社 感熱転写材料及び該材料に好適な色素
DE19704923A1 (de) 1997-02-10 1998-08-13 Hoechst Schering Agrevo Gmbh Klebstoffhaltige Schädlingsbekämpfungsmittel
WO2001032013A1 (en) 1999-11-04 2001-05-10 Colorado State University Research Foundation Method and device for attracting insects
FR2801587B1 (fr) 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA04003297A (es) * 2001-10-10 2004-07-23 Neurosearch As Derivados novedosos de benzotiacina su preparacion y uso.
FR2833955B1 (fr) * 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) * 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2865474B1 (fr) 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) * 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2655376A1 (en) 2006-06-23 2007-12-27 Nufarm Australia Limited Phenoxy alkanoate herbicidal composition and method of preparation and use
EP2102153A1 (en) * 2006-12-11 2009-09-23 Eli Lilly & Company Ampa receptor potentiators
US20080167374A1 (en) 2007-01-09 2008-07-10 Loveland Products, Inc. Pesticide composition and method of use
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110118236A1 (en) 2008-03-25 2011-05-19 Michiyo Mochizuki Heterocyclic compound
JP2009248543A (ja) * 2008-04-11 2009-10-29 Fujifilm Corp 光情報記録媒体および情報記録方法
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
EP2356115A1 (en) 2008-11-06 2011-08-17 Schering Corporation Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010140339A1 (ja) 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
JPWO2011007756A1 (ja) 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
HRP20200844T1 (hr) * 2010-08-10 2020-08-21 Takeda Pharmaceutical Company Limited Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora ampa-receptora

Also Published As

Publication number Publication date
US20150353578A1 (en) 2015-12-10
NZ607593A (en) 2015-01-30
US20170022222A1 (en) 2017-01-26
MY165908A (en) 2018-05-18
WO2012020848A1 (en) 2012-02-16
BR112013002250A2 (pt) 2016-05-24
GEP20156216B (en) 2015-01-12
TW201217386A (en) 2012-05-01
EP2603513B1 (en) 2020-03-11
MA34509B1 (fr) 2013-09-02
AU2011290126A1 (en) 2013-03-07
MX2013001614A (es) 2013-07-05
HUE049460T2 (hu) 2020-09-28
US20190263832A1 (en) 2019-08-29
SI2603513T1 (sl) 2020-07-31
UA111594C2 (uk) 2016-05-25
CN103180326A (zh) 2013-06-26
KR101852215B1 (ko) 2018-04-25
DK2603513T3 (da) 2020-06-15
US8575154B2 (en) 2013-11-05
US20130184266A1 (en) 2013-07-18
PT2603513T (pt) 2020-06-08
US20240360156A1 (en) 2024-10-31
CN104926837A (zh) 2015-09-23
US20130190291A1 (en) 2013-07-25
CR20130066A (es) 2013-05-03
CA2807460C (en) 2018-09-18
US8778934B2 (en) 2014-07-15
ES2793723T3 (es) 2020-11-16
HRP20200844T1 (hr) 2020-08-21
US11279713B2 (en) 2022-03-22
US20150073137A1 (en) 2015-03-12
PE20131116A1 (es) 2013-10-24
SG187656A1 (en) 2013-03-28
TWI504604B (zh) 2015-10-21
US9499568B2 (en) 2016-11-22
PL2603513T3 (pl) 2020-07-27
PH12013500247A1 (en) 2013-03-11
ECSP13012478A (es) 2013-04-30
US9884875B2 (en) 2018-02-06
RS60311B1 (sr) 2020-07-31
KR20130138738A (ko) 2013-12-19
JP5788496B2 (ja) 2015-09-30
CY1123507T1 (el) 2022-03-24
US20180162875A1 (en) 2018-06-14
CO6680700A2 (es) 2013-05-31
US20200317692A1 (en) 2020-10-08
DOP2013000030A (es) 2013-03-15
EA201390222A1 (ru) 2013-08-30
EA022078B1 (ru) 2015-10-30
JP2016006080A (ja) 2016-01-14
US20120077799A1 (en) 2012-03-29
LT2603513T (lt) 2020-05-25
AR082618A1 (es) 2012-12-19
JP6113789B2 (ja) 2017-04-12
BR112013002250B1 (pt) 2020-10-27
ZA201301120B (en) 2014-04-30
MX349470B (es) 2017-07-31
CA2807460A1 (en) 2012-02-16
AU2011290126B2 (en) 2016-01-07
WO2012020848A8 (en) 2012-09-27
UY33551A (es) 2012-03-30
IL224452A (en) 2017-11-30
US20140080817A1 (en) 2014-03-20
EP2603513A1 (en) 2013-06-19
JP2013535408A (ja) 2013-09-12
US8916551B2 (en) 2014-12-23
US10654874B2 (en) 2020-05-19
CN103180326B (zh) 2015-06-10
US9150591B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
CL2012001762A1 (es) Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve.
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
CL2012002771A1 (es) Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
CR20110103A (es) Heteroarilos sustituidos
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
UY33276A (es) Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2